Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease

H. Gondo, M. Harada, S. Taniguchi, Koichi Akashi, S. Hayashi, T. Teshima, Y. Takamatsu, T. Eto, K. Nagafuji, K. Yamasaki, T. Shibuya, Y. Niho

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To evaluate the efficacy of cyclosporine (CYA) regimens in preventing moderate to severe acute graft-versus-host disease (GVHD), 25 patients received immunosuppressive therapy consisting of either CYA and methylprednisolone or CYA and methotrexate (MTX) and the incidence and severity of acute GVHD was compared. These patients had leukemia or myelodysplastic syndrome (MDS) and received bone marrow transplants (BMT) from genotypically HLA-identical siblings. The incidence of grade I-IV acute GVHD in patients on the CYA/methylprednisolone regimen was 64% (7 of 11) compared with 50% (7 of 14) in those on the CYA MTX regimen. Five of 11 patients with the CYA/methylprednisolone regimen developed moderate to severe acute GVHD (grade II-IV), fatal in 3 cases. No patient on the CYA/MTX regimen developed moderate to severe acute GVHD. Engraftment was faster in the CYA/methylprednisolone group than in the CYA/MTX group. The incidence of toxicity observed soon after BMT was comparable between groups. The CYA MTX regimen may be superior to the CYA/methylprednisolone regimen for preventing moderate to severe acute GVHD.

Original languageEnglish
Pages (from-to)437-441
Number of pages5
JournalBone Marrow Transplantation
Volume12
Issue number5
Publication statusPublished - 1993

Fingerprint

Methylprednisolone
Graft vs Host Disease
Methotrexate
Cyclosporine
Incidence
Bone Marrow
Transplants
Myelodysplastic Syndromes
Immunosuppressive Agents
Siblings
Leukemia

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. / Gondo, H.; Harada, M.; Taniguchi, S.; Akashi, Koichi; Hayashi, S.; Teshima, T.; Takamatsu, Y.; Eto, T.; Nagafuji, K.; Yamasaki, K.; Shibuya, T.; Niho, Y.

In: Bone Marrow Transplantation, Vol. 12, No. 5, 1993, p. 437-441.

Research output: Contribution to journalArticle

Gondo, H, Harada, M, Taniguchi, S, Akashi, K, Hayashi, S, Teshima, T, Takamatsu, Y, Eto, T, Nagafuji, K, Yamasaki, K, Shibuya, T & Niho, Y 1993, 'Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease', Bone Marrow Transplantation, vol. 12, no. 5, pp. 437-441.
Gondo, H. ; Harada, M. ; Taniguchi, S. ; Akashi, Koichi ; Hayashi, S. ; Teshima, T. ; Takamatsu, Y. ; Eto, T. ; Nagafuji, K. ; Yamasaki, K. ; Shibuya, T. ; Niho, Y. / Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. In: Bone Marrow Transplantation. 1993 ; Vol. 12, No. 5. pp. 437-441.
@article{99e7bf74a31a4c4abe06953d9b6eac3d,
title = "Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease",
abstract = "To evaluate the efficacy of cyclosporine (CYA) regimens in preventing moderate to severe acute graft-versus-host disease (GVHD), 25 patients received immunosuppressive therapy consisting of either CYA and methylprednisolone or CYA and methotrexate (MTX) and the incidence and severity of acute GVHD was compared. These patients had leukemia or myelodysplastic syndrome (MDS) and received bone marrow transplants (BMT) from genotypically HLA-identical siblings. The incidence of grade I-IV acute GVHD in patients on the CYA/methylprednisolone regimen was 64{\%} (7 of 11) compared with 50{\%} (7 of 14) in those on the CYA MTX regimen. Five of 11 patients with the CYA/methylprednisolone regimen developed moderate to severe acute GVHD (grade II-IV), fatal in 3 cases. No patient on the CYA/MTX regimen developed moderate to severe acute GVHD. Engraftment was faster in the CYA/methylprednisolone group than in the CYA/MTX group. The incidence of toxicity observed soon after BMT was comparable between groups. The CYA MTX regimen may be superior to the CYA/methylprednisolone regimen for preventing moderate to severe acute GVHD.",
author = "H. Gondo and M. Harada and S. Taniguchi and Koichi Akashi and S. Hayashi and T. Teshima and Y. Takamatsu and T. Eto and K. Nagafuji and K. Yamasaki and T. Shibuya and Y. Niho",
year = "1993",
language = "English",
volume = "12",
pages = "437--441",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease

AU - Gondo, H.

AU - Harada, M.

AU - Taniguchi, S.

AU - Akashi, Koichi

AU - Hayashi, S.

AU - Teshima, T.

AU - Takamatsu, Y.

AU - Eto, T.

AU - Nagafuji, K.

AU - Yamasaki, K.

AU - Shibuya, T.

AU - Niho, Y.

PY - 1993

Y1 - 1993

N2 - To evaluate the efficacy of cyclosporine (CYA) regimens in preventing moderate to severe acute graft-versus-host disease (GVHD), 25 patients received immunosuppressive therapy consisting of either CYA and methylprednisolone or CYA and methotrexate (MTX) and the incidence and severity of acute GVHD was compared. These patients had leukemia or myelodysplastic syndrome (MDS) and received bone marrow transplants (BMT) from genotypically HLA-identical siblings. The incidence of grade I-IV acute GVHD in patients on the CYA/methylprednisolone regimen was 64% (7 of 11) compared with 50% (7 of 14) in those on the CYA MTX regimen. Five of 11 patients with the CYA/methylprednisolone regimen developed moderate to severe acute GVHD (grade II-IV), fatal in 3 cases. No patient on the CYA/MTX regimen developed moderate to severe acute GVHD. Engraftment was faster in the CYA/methylprednisolone group than in the CYA/MTX group. The incidence of toxicity observed soon after BMT was comparable between groups. The CYA MTX regimen may be superior to the CYA/methylprednisolone regimen for preventing moderate to severe acute GVHD.

AB - To evaluate the efficacy of cyclosporine (CYA) regimens in preventing moderate to severe acute graft-versus-host disease (GVHD), 25 patients received immunosuppressive therapy consisting of either CYA and methylprednisolone or CYA and methotrexate (MTX) and the incidence and severity of acute GVHD was compared. These patients had leukemia or myelodysplastic syndrome (MDS) and received bone marrow transplants (BMT) from genotypically HLA-identical siblings. The incidence of grade I-IV acute GVHD in patients on the CYA/methylprednisolone regimen was 64% (7 of 11) compared with 50% (7 of 14) in those on the CYA MTX regimen. Five of 11 patients with the CYA/methylprednisolone regimen developed moderate to severe acute GVHD (grade II-IV), fatal in 3 cases. No patient on the CYA/MTX regimen developed moderate to severe acute GVHD. Engraftment was faster in the CYA/methylprednisolone group than in the CYA/MTX group. The incidence of toxicity observed soon after BMT was comparable between groups. The CYA MTX regimen may be superior to the CYA/methylprednisolone regimen for preventing moderate to severe acute GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0027425132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027425132&partnerID=8YFLogxK

M3 - Article

C2 - 8298553

AN - SCOPUS:0027425132

VL - 12

SP - 437

EP - 441

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -